BioCentury | Mar 13, 2018
Distillery Therapeutics

Cancer

...Feb. 22, 2017. doi:10.1021/acs.jmedchem.7b01837 CONTACT: Maurizio Pellecchia, University of California Riverside, Riverside, Calif. email: maurizio.pellecchia@ucr.edu Elizabeth S. Eaton Abraxane, nab-paclitaxel (ABI-007) University of California Riverside EPH...
BioCentury | Jan 4, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: December 2017

...Mouse and cell culture studies suggest RETN or an RETN-derived peptide could help treat sepsis. University of California Riverside...
BioCentury | Dec 19, 2017
Distillery Therapeutics

Infectious disease

...13, 2017 doi:10.1073/pnas.1716015114 CONTACT: Meera G. Nair, University of California, Riverside, Calif. email: meera.nair@ucr.edu Karen Tkach Tuzman University of California Riverside Resistin...
BioCentury | Mar 31, 2017
Clinical News

Teams describe Zika NS5 protein's crystal structure

...domain that could inform design of anti-Zika non-nucleoside polymerase inhibitors. A third group from the University of California Riverside...
...with dengue virus are needed (see BioCentury Innovations, Dec. 21, 2016) . Mary Romeo Indiana University Texas A&M University University of California Riverside Zika...
BioCentury | Aug 15, 2013
Cover Story

B cell lymphoma and the microbiome

A key challenge in mining the microbiome for therapeutic strategies has been to characterize the functional role of specific bacterial populations in the context of a disease. Now, University of California researchers have shown the...
BioCentury | Aug 15, 2013
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer B cell lymphoma Unknown Mouse studies suggest Lactobacillus johnsonii supplementation could help prevent ataxia-telangiectasia−associated B cell lymphomas. In a mouse model of ataxia telangiectasia, mice...
BioCentury | Sep 16, 2010
Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Culture of human pluripotent stem (hPS) cells in non-muscle myosin II (MYH10; NMHCII)-depleted conditions to improve viability and increase available cells for clinical applications...
BioCentury | Jun 26, 2008
Cover Story

New Area in Malaria

Development of malaria therapeutics has been stymied by poor understanding of drug targets and limited corporate interest in picking up preclinical compounds with therapeutic promise. At the same time, the parasite has shown mounting resistance...
BioCentury | Jun 26, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/ marker/pathway Summary Licensing status Publication and contact information Infectious disease Malaria Proteasome An in vitro screening study suggests that the proteasome inhibitor salinosporamide A could be used to treat...
BioCentury | Dec 17, 2001
Company News

Alydar Pharmaceuticals Inc. scientific advisory board update

Alydar Pharmaceuticals Inc. , Mountain View, Calif. Business: Cardiovascular, Neurological, Cancer Appointed: Thomas Eisner, professor of chemical ecology at Cornell University; Jerrold Meinwald, professor of chemistry at Cornell University; and Jocelyn Millar, professor of entomology at...
Items per page:
1 - 10 of 13
BioCentury | Mar 13, 2018
Distillery Therapeutics

Cancer

...Feb. 22, 2017. doi:10.1021/acs.jmedchem.7b01837 CONTACT: Maurizio Pellecchia, University of California Riverside, Riverside, Calif. email: maurizio.pellecchia@ucr.edu Elizabeth S. Eaton Abraxane, nab-paclitaxel (ABI-007) University of California Riverside EPH...
BioCentury | Jan 4, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: December 2017

...Mouse and cell culture studies suggest RETN or an RETN-derived peptide could help treat sepsis. University of California Riverside...
BioCentury | Dec 19, 2017
Distillery Therapeutics

Infectious disease

...13, 2017 doi:10.1073/pnas.1716015114 CONTACT: Meera G. Nair, University of California, Riverside, Calif. email: meera.nair@ucr.edu Karen Tkach Tuzman University of California Riverside Resistin...
BioCentury | Mar 31, 2017
Clinical News

Teams describe Zika NS5 protein's crystal structure

...domain that could inform design of anti-Zika non-nucleoside polymerase inhibitors. A third group from the University of California Riverside...
...with dengue virus are needed (see BioCentury Innovations, Dec. 21, 2016) . Mary Romeo Indiana University Texas A&M University University of California Riverside Zika...
BioCentury | Aug 15, 2013
Cover Story

B cell lymphoma and the microbiome

A key challenge in mining the microbiome for therapeutic strategies has been to characterize the functional role of specific bacterial populations in the context of a disease. Now, University of California researchers have shown the...
BioCentury | Aug 15, 2013
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer B cell lymphoma Unknown Mouse studies suggest Lactobacillus johnsonii supplementation could help prevent ataxia-telangiectasia−associated B cell lymphomas. In a mouse model of ataxia telangiectasia, mice...
BioCentury | Sep 16, 2010
Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Culture of human pluripotent stem (hPS) cells in non-muscle myosin II (MYH10; NMHCII)-depleted conditions to improve viability and increase available cells for clinical applications...
BioCentury | Jun 26, 2008
Cover Story

New Area in Malaria

Development of malaria therapeutics has been stymied by poor understanding of drug targets and limited corporate interest in picking up preclinical compounds with therapeutic promise. At the same time, the parasite has shown mounting resistance...
BioCentury | Jun 26, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/ marker/pathway Summary Licensing status Publication and contact information Infectious disease Malaria Proteasome An in vitro screening study suggests that the proteasome inhibitor salinosporamide A could be used to treat...
BioCentury | Dec 17, 2001
Company News

Alydar Pharmaceuticals Inc. scientific advisory board update

Alydar Pharmaceuticals Inc. , Mountain View, Calif. Business: Cardiovascular, Neurological, Cancer Appointed: Thomas Eisner, professor of chemical ecology at Cornell University; Jerrold Meinwald, professor of chemistry at Cornell University; and Jocelyn Millar, professor of entomology at...
Items per page:
1 - 10 of 13